Idiopathic pulmonary fibrosis: an Australian perspective

J Prasad; A E Holland; I Glaspole; G Westall

doi:10.1111/imj.13078

Idiopathic pulmonary fibrosis: an Australian perspective

Intern Med J. 2016 Jun;46(6):663-8. doi: 10.1111/imj.13078.

Authors

J Prasad^{1

2}, A E Holland^{1

3}, I Glaspole¹, G Westall^{1

2}

Affiliations

¹ Allergy Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Victoria, Australia.
² Clinical School of Medicine, Monash University, Melbourne, Victoria, Australia.
³ Department of Physiotherapy, La Trobe University, Melbourne, Victoria, Australia.

PMID: 27257148
DOI: 10.1111/imj.13078

Abstract

Idiopathic pulmonary fibrosis is a progressive interstitial lung disease of unknown aetiology with a dismal median survival of 3 years. Patients typically develop progressive dyspnoea and increasing exercise limitation. With a rising incidence and prevalence, an unpredictable disease course and limited treatment options, it is rapidly becoming an important public health concern. To date, lung transplantation has been the sole viable hope for treatment for those who qualify. However, the landscape of idiopathic pulmonary fibrosis management is changing, with the recent emergence of novel pharmacotherapy shown to have a favourable influence on the natural history of this disease.

Keywords: IPF MDM; IPF exacerbation; IPF review; IPF transplant; IPF treatment; idiopathic pulmonary fibrosis.

Publication types

Review

MeSH terms

Australia / epidemiology
Disease Management
Drug Therapy
Humans
Idiopathic Pulmonary Fibrosis / diagnostic imaging
Idiopathic Pulmonary Fibrosis / drug therapy*
Idiopathic Pulmonary Fibrosis / epidemiology*
Idiopathic Pulmonary Fibrosis / surgery*
Incidence
Lung Transplantation*
Risk Factors
Tomography, X-Ray Computed